In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML

Mutation-Agnostic Treatment Advances

 
• By Sushmita Panda
  
Cancer Cells
Aptose reports promising results for triplet therapy for mutation-agnostic frontline AML. (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from Therapy Areas